Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Costco Wholesale Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Costco Wholesale Corporation trades at $954.19 (market cap $420.20B). The key difference: Costco Wholesale Corporation is far larger — about 93.6× ACADIA Pharmaceuticals Inc.'s market cap, and Costco Wholesale Corporation pays a 0.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | COST | |
|---|---|---|
Market Cap | $4.49B | $420.20B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $1.09K |
52-Week Low | $20.06 | $849.63 |
Enterprise Value | $3.69B | $408.34B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Costco (COST) trades at $953.55, up 0.35% with a bearish technical signal despite strong fundamentals. The company reported solid March sales growth of 11.3% year-over-year and maintains consistent revenue and earnings growth. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,110 price target, though valuation metrics appear elevated with a P/E of 47.7.
The stock faces near-term technical pressure but benefits from strong membership fee growth and expanding profitability. Key risks include premium valuation compression and competitive pressures, while catalysts include sustained membership renewal strength and international expansion opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
